XTL Biopharmaceuticals Ltd XTLB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 982.99M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 0.80
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 5
- Website
- https://www.xtlbio.com
Valuation
|
Metric
|
XTLB
|
|---|---|
Price/Earnings (Normalized) | 0.80 |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
XTLB
Financial Strength
|
Metric
|
XTLB
|
|---|---|
Quick Ratio | 0.34 |
Current Ratio | 0.40 |
Interest Coverage | −116.00 |
Quick Ratio
XTLB
Profitability
|
Metric
|
XTLB
|
|---|---|
Return on Assets (Normalized) | 166.10% |
Return on Equity (Normalized) | 305.08% |
Return on Invested Capital (Normalized) | 275.53% |
Return on Assets
XTLB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%?b&zS | LOCK|%l#S | $123B | |||
| Moderna Inc
MRNA
| LOCK|Wf&>%G& | LOCK|<L | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|jKr<>T | LOCK|Tz^V | $78B | |||
| argenx SE ADR
ARGX
| LOCK|#HFzTwx | LOCK|<bW | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%c@$k## | LOCK|r^b | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|B?%H&# | LOCK|b%FH | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Hxq%>^DV | LOCK|X<H# | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|J^$&Q># | LOCK|kBY | $22B | |||
| Incyte Corp
INCY
| LOCK|<j$gW#p | LOCK|p^% | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&<HcS% | LOCK|%^$ | $14B |
United States